China's CSPC Pharmaceutical Group to partner with AstraZeneca for renal disease drug

Category: Markets

Published: 2026-07-02T08:56:41.000Z

China's CSPC Pharmaceutical Group is set to partner with AstraZeneca on a renal disease drug. This collaboration marks another strategic alliance for AstraZeneca in the pharmaceutical sector, following recent partnerships for non-small cell lung cancer treatments. The full details of this specific agreement are reserved for members of the platform.

Read the original source

News summary curated and translated by CausifyMarket. Always consult original sources before making any financial decision.